Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
Trial details
- Registry ID
- NCT06515418
- Phase
- Phase 2
The FDA approved Tirzepatide (ZEPBOUND) on 13 May 2022.
Drug identity checked against registry records
Also recorded as ZEPBOUND
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and OverNCT06515418 | BIOA | Phase 2 | Terminated | 2025-02-06Actual |
| Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseNCT06445075 | Scholar Rock, Inc. | Phase 2 | Completed | 2025-03-04Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2022-05-13Day | Tirzepatide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA215866", "applicant_as_listed_by_fda": "ELI LILLY AND CO", "brand_names": ["MOUNJARO", "MOUNJARO (AUTOINJECTOR)", "MOUNJARO KWIKPEN"], "active_ingredients": ["TIRZEPATIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20220513", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |